ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy

Journal of the American College of Cardiology

Volumn 61, Issue 12, 2013, Pages 1318-1368

  Russo, Andrea M ^a,b   Stainback, Raymond F ^c,d   Bailey, Steven R ^e   Epstein, Andrew E ^f,g   Heidenreich, Paul A ^h   Jessup, Mariell ⁱ   Kapa, Suraj ^f   Kremers, Mark S ^j   Lindsay, Bruce D ^k   Stevenson, Lynne Warner ^l   Alexander, Michael B ^m   Birgersdotter Green, Ulrika ^n,o   Brown, Alan S ^p   Grimm, Richard A ^k   Hauptman, Paul J ^q,r   Hunt, Sharon A ^h   Lampert, Rachel ^s   Lindenfeld, Joann ^t   Malenka, David J ^u   Mani, Kartik ^v   Marine, Joseph E ^w   Martin, Edward T ^x   Page, Richard L ^y   Rich, Michael W ^z   Varosy, Paul D ^aa   Walsh, Mary Norine ^ab   Wolk, Michael J ^ac   Doherty, John U ^ad   Douglas, Pamela S ^ah   Hendel, Robert C ^ae   Kramer, Christopher M ^af   Min, James K ^ag   Patel, Manesh R ^ah   Shaw, Leslee ^ai   Allen, Joseph M ^aj   more..

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Department of Anesthesiology   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j Mid Carolina Cardiology   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

^l BRIGHAM AND WOMEN S HOSPITAL   (United States)

^m Cigna   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p LOYOLA UNIVERSITY CHICAGO   (United States)

^q SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

^r SAINT LOUIS UNIVERSITY   (United States)

^s YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^t UNIVERSITY OF COLORADO   (United States)

^u DARTMOUTH MEDICAL SCHOOL   (United States)

^v Mercy Medical Center   (United States)

^w JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^x UNIVERSITY OF OKLAHOMA   (United States)

^y UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^z WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^aa UNIVERSITY OF COLORADO   (United States)

^ab St Vincent s Heart Center of Indiana   (United States)

^ac WEILL CORNELL MEDICAL COLLEGE   (United States)

^ad THOMAS JEFFERSON UNIVERSITY   (United States)

^ae UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^af UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^ag CEDARS SINAI MEDICAL CENTER   (United States)

^ah DUKE UNIVERSITY MEDICAL CENTER   (United States)

^ai EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^aj AMERICAN COLLEGE OF CARDIOLOGY   (United States)

more..

Author keywords

ACCF appropriate use criteria; CRT; Electrophysiology; Heart failure; ICD; Implantable defibrillator; Sudden death

Indexed keywords

APPROPRIATE USE CRITERIA; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; COMORBIDITY; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IMPLANTATION; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; TREATMENT INDICATION; ADVISORY COMMITTEE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM EXAMINATION; HEALTH CARE QUALITY; HEALTH SERVICES RESEARCH; MEDICAL SOCIETY; STANDARD; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

ADVISORY COMMITTEES; AMERICAN HEART ASSOCIATION; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR DISEASES; COMORBIDITY; DEFIBRILLATORS, IMPLANTABLE; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; GUIDELINE ADHERENCE; HEALTH SERVICES RESEARCH; HUMANS; PRACTICE GUIDELINES AS TOPIC; QUALITY ASSURANCE, HEALTH CARE; UNITED STATES; UTILIZATION REVIEW;

EID: 84877284718     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.12.017     Document Type: Article

References (61)

1. Douglas PS, Garcia MJ, Haines DE, et al. ACCF/ASE/AHA/ ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol 2011;57: 1126 - 66.
2. Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/ AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol 2010;56:1864 -94.
3. Hendel RC, Berman DS, Di Carli MF, et al. ACCF/ASNC/ACR/ AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for cardiac radionuclide imaging: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. J Am Coll Cardiol 2009;53: 2201-29.
4. Patel MR, Dehmer GJ, Hirshfeld JW, et al. ACCF/SCAI/STS/ AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 2012;59:857- 81.
5. Patel MR, Bailey SR, Bonow RO, et al. ACCF/SCAI/AATS/AHA/ ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 appropriate use criteria for diagnostic catheterization: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012;59:1995-2027.
6. Patel MR, Spertus JA, Brindis RG, et al. ACCF proposed method for evaluating the appropriateness of cardiovascular imaging. J Am Coll Cardiol 2005;56:1606 -13.
7. Hendel RC, Patel MR, Allen JM. Appropriate use of cardiovascular technology: 2013 ACCF appropriate use criteria methodology update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force. J Am Coll Cardiol 2013;61:1305-17.
8. Fitch K, Bernstein SJ, Aguilar MD, et al. The RAND/UCLA Appropriateness Method User's Manual. Arlington, VA: RAND, 2001.
9. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). J Am Coll Cardiol 2008;51:e1- 62.
10. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Implantable Automatic Defibrillators (20.4). 2005. Available at: http://www.cms.gov/medicare-coverage-database/details/ ncd-details.aspx?NCDId-110&ncdver-3&bc-AAAAgAAAAAAA&. Accessed September 5, 2012.
11. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877- 83.
12. Naccarelli GV, Conti JB, DiMarco JP, Tracy CM. Task force 6: training in specialized electrophysiology, cardiac pacing, and arrhythmia management. J Am Coll Cardiol 2008;51:374-80.
13. Hammill SC, Kremers MS, Stevenson LW, et al. Review of the registry's fourth year, incorporating lead data and pediatric ICD procedures, and use as a national performance measure. Heart Rhythm 2010;7:1340 -5.
14. Barsheshet A, Moss AJ, McNitt S, et al. Long-term implications of cumulative right ventricular pacing among patients with an implantable cardioverter-defibrillator. Heart Rhythm 2011;8:212- 8.
15. Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) trial. JAMA 2002;288:3115-23.
16. Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 2003;107:2932-7.
17. Gillis AM, Russo AM, Ellenbogen KA, et al. HRS/ACCF expert consensus statement on pacemaker device and mode selection: developed in partnership between the Heart Rhythm Society (HRS) and the American College of Cardiology Foundation (ACCF) and in collaboration with the Society of Thoracic Surgeons. Heart Rhythm 2012;9:1344-65.
18. Theuns DA, Rivero-Ayerza M, Boersma E, Jordaens L. Prevention of inappropriate therapy in implantable defibrillators: a meta-analysis of clinical trials comparing single-chamber and dual-chamber arrhythmia discrimination algorithms. Int J Cardiol 2008;125:352-7.
19. Beshai JF, Grimm RA, Nagueh SF, et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med 2007;357:2461-71.
20. Sipahi I, Carrigan TP, Rowland DY, et al. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: metaanalysis of randomized controlled trials. Arch Intern Med 2011;171: 1454-62.
21. Stavrakis S, Lazzara R, Thadani U. The benefit of cardiac resynchronization therapy and QRS duration: a meta-analysis. J Cardiovasc Electrophysiol 2012;23:163- 8.
22. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults :a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;53:e1-90.
23. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol 2007;50:2173-95.
24. Agewall S, Giannitsis E, Jernberg T, Katus H. Troponin elevation in coronary vs. non-coronary disease. Eur Heart J 2011;32:404 -11.
25. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581-98.
26. Fye WB. Troponin trumps common sense. J Am Coll Cardiol 2006;48:2357- 8.
27. Heart Failure Society of America. NYHA Classification: The Stages of Heart Failure. March 2012. Available at: http://www.abouthf.org/ questions-stages.htm. Accessed March 2012.
28. NCDR ICD Registry. Elements and Definitions. 2011.
29. Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2013;61:e6 -75.
30. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481- 8.
31. Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009;361:1427-36.
32. Wilkoff BL, Williamson BD, Stern RS, et al. Strategic programming of detection and therapy parameters in implantable cardioverterdefibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol 2008;52:541-50.
33. Hatzinikolaou-Kotsakou E, Tziakas D, Hotidis A, et al. Could sustained monomorphic ventricular tachycardia in the early phase of a prime acute myocardial infarction affect patient outcome? J Electrocardiol 2007;40:72-7.
34. Mont L, Cinca J, Blanch P, et al. Predisposing factors and prognostic value of sustained monomorphic ventricular tachycardia in the early phase of acute myocardial infarction. J Am Coll Cardiol 1996;28: 1670-6.
35. Chen X, Shenasa M, Borggrefe M, et al. Role of programmed ventricular stimulation in patients with idiopathic dilated cardiomyopathy and documented sustained ventricular tachyarrhythmias: inducibility and prognostic value in 102 patients. Eur Heart J 1994;15: 76-82.
36. Buxton AE, Lee KL, Fisher JD, et al., Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882-90.
37. Pires LA, Hafley GE, Lee KL, et al., Multicenter Unsustained Tachycardia Trial Investigators. Prognostic significance of nonsustained ventricular tachycardia identified postoperatively after coronary artery bypass surgery in patients with left ventricular dysfunction. J Cardiovasc Electrophysiol 2002;13:757- 63.
38. Poole JE, Gleva MJ, Mela T, et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation 2010;122:1553- 61.
39. Kreuz J, Horlbeck F, Schrickel J, et al. Kidney dysfunction and deterioration of ejection fraction pose independent risk factors for mortality in implantable cardioverter-defibrillator recipients for primary prevention. Clin Cardiol 2012;35:575-9.
40. Charytan DM, Patrick AR, Liu J, et al. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis 2011;58:409 -17.
41. Tompkins C, McLean R, Cheng A, et al. End-stage renal disease predicts complications in pacemaker and ICD implants. J Cardiovasc Electrophysiol 2011;22:1099 -104.
42. Kramer DB, Friedman PA, Kallinen LM, et al. Development and validation of a risk score to predict early mortality in recipients of implantable cardioverter-defibrillators. Heart Rhythm 2012;9:42- 6.
43. Barsheshet A, Moss AJ, Huang DT, et al. Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator. J Am Coll Cardiol 2012;59:2075-9.
44. Lee DS, Tu JV, Austin PC, et al. Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. J Am Coll Cardiol 2007;49:2408 -15.
45. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
46. Epstein AE, Kay GN, Plumb VJ, et al. Implantable cardioverterdefibrillator prescription in the elderly. Heart Rhythm 2009;6: 1136 - 43.
47. Kremers MS, Hammill SC, Koutras C, et al. NCDR ICD Registry Version 2 Data: Years 2010-2011. 2012.
48. Goldenberg I, Moss AJ, McNitt S, et al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol 2006;98:485-90.
49. Cuculich PS, Sanchez JM, Kerzner R, et al. Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death. Pacing Clin Electrophysiol 2007;30:207-13.
50. Dupont M, Rickard J, Baranowski B, et al. Differential response to cardiac resynchronization therapy and clinical outcomes according to QRS morphology and QRS duration. J Am Coll Cardiol 2012;60:592-8.
51. Nery PB, Ha AC, Keren A, Birnie DH. Cardiac resynchronization therapy in patients with left ventricular systolic dysfunction and right bundle branch block: a systematic review. Heart Rhythm 2011;8:1083-7.
52. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329 -38.
53. Sharma AD, Rizo-Patron C, Hallstrom AP, et al. Percent right ventricular pacing predicts outcomes in the DAVID trial. Heart Rhythm 2005;2:830-4.
54. Steinberg JS, Fischer A, Wang P, et al. The clinical implications of cumulative right ventricular pacing in the multicenter automatic defibrillator trial II. J Cardiovasc Electrophysiol 2005;16:359-65.
55. Smit MD, Van Dessel PF, Nieuwland W, et al. Right ventricular pacing and the risk of heart failure in implantable cardioverterdefibrillator patients. Heart Rhythm 2006;3:1397- 403.
56. Kramer DB, Buxton AE, Zimetbaum PJ. Time for a change-a new approach to ICD replacement. N Engl J Med 2012;366:291-3.
57. Dewland TA, Pellegrini CN, Wang Y , et al. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. J Am Coll Cardiol 2011;58:1007-13.
58. Lee DS, Krahn AD, Healey JS, et al. Evaluation of early complications related to de novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol 2010;55:774 - 82.
59. Matlock DD, Peterson PN, Wang Y, et al. Variation in use of dual-chamber implantable cardioverter-defibrillators: results from the National Cardiovascular Data Registry. Arch Intern Med 2012;172: 634-41.
60. Mehra MR, Yancy CW, Albert NM, et al. Evidence of clinical practice heterogeneity in the use of implantable cardioverterdefibrillators in heart failure and post-myocardial infarction left ventricular dysfunction: findings from IMPROVE HF. Heart Rhythm 2009;6:1727-34.
61. Hernandez AF, Fonarow GC, Liang L, et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA 2007;298:1525-32.